Co-Authors
This is a "connection" page, showing publications co-authored by Hunter Moore and Daniel Talmor.
Connection Strength
0.609
-
Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome? J Trauma Acute Care Surg. 2020 06; 88(6):713-714.
Score: 0.221
-
STudy of Alteplase for Respiratory failure in SARS-Cov2/COVID-19: Study Design of the Phase IIa STARS Trial. Res Pract Thromb Haemost. 2020 May 21.
Score: 0.221
-
Rescue therapy for severe COVID-19-associated acute respiratory distress syndrome with tissue plasminogen activator: A case series. J Trauma Acute Care Surg. 2020 09; 89(3):453-457.
Score: 0.056
-
Fibrinolytic therapy for refractory COVID-19 acute respiratory distress syndrome: Scientific rationale and review. Res Pract Thromb Haemost. 2020 May; 4(4):524-531.
Score: 0.055
-
Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis. World J Emerg Surg. 2020 04 20; 15(1):29.
Score: 0.055